Cargando…
A phase I/II trial of hydroxychloroquine in conjunction with radiation therapy and concurrent and adjuvant temozolomide in patients with newly diagnosed glioblastoma multiforme
Preclinical studies indicate autophagy inhibition with hydroxychloroquine (HCQ) can augment the efficacy of DNA-damaging therapy. The primary objective of this trial was to determine the maximum tolerated dose (MTD) and efficacy of HCQ in combination with radiation therapy (RT) and temozolomide (TMZ...
Autores principales: | Rosenfeld, Myrna R, Ye, Xiaobu, Supko, Jeffrey G, Desideri, Serena, Grossman, Stuart A, Brem, Steven, Mikkelson, Tom, Wang, Daniel, Chang, Yunyoung C, Hu, Janice, McAfee, Quentin, Fisher, Joy, Troxel, Andrea B, Piao, Shengfu, Heitjan, Daniel F, Tan, Kay-See, Pontiggia, Laura, O’Dwyer, Peter J, Davis, Lisa E, Amaravadi, Ravi K |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Landes Bioscience
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4203513/ https://www.ncbi.nlm.nih.gov/pubmed/24991840 http://dx.doi.org/10.4161/auto.28984 |
Ejemplares similares
-
Phase I trial of hydroxychloroquine with dose-intense temozolomide in patients with advanced solid tumors and melanoma
por: Rangwala, Reshma, et al.
Publicado: (2014) -
A Multi-Site Phase I Trial of Veliparib with Standard Radiation and Temozolomide in Patients with Newly Diagnosed Glioblastoma Multiforme (GBM)
por: Kleinberg, Lawrence, et al.
Publicado: (2023) -
Combined MTOR and autophagy inhibition: Phase I trial of hydroxychloroquine and temsirolimus in patients with advanced solid tumors and melanoma
por: Rangwala, Reshma, et al.
Publicado: (2014) -
Temozolomide resistance in glioblastoma multiforme
por: Lee, Sang Y.
Publicado: (2016) -
Effectiveness of temozolomide for primary glioblastoma multiforme in routine clinical practice
por: van Genugten, J. A. B., et al.
Publicado: (2009)